THE KYBELLA® CONVERSATION

The first step in considering treatment with KYBELLA® is to bring up the topic of submental fullness during consultation.
Help patients understand submental fullness by talking to them about their sloped chin profile line.

slopped-chin-line
play-icon

Where do you
Draw the line?

  • Educates on the sloped chin profile line and how you can use the term with patients
Kybella conversation
pdf-icon

Conversation Starters

  • Examples of how to talk to different patient types about KYBELLA®
  • Patient selection criteria and the 5 simple tests to assess baseline anatomy

PATIENT SELECTION & TREATMENT PLANNING

Select patients appropriate for KYBELLA® and guide them through a full treatment series
for optimal reduction of submental fullness.

Next Patient
pdf-icon

Identify Your Next
KYBELLA® Patient

  • Tips for including KYBELLA® in your patient consultations
  • Anatomic considerations when selecting appropriate patients
Treatment Series
pdf-icon

Treatment Planning
Tear Pad

  • Overview of KYBELLA® Assessment, Consultation, and Treatment (ACT) key elements
  • Patient Treatment Plan Tracker to keep your patients’ treatment series organized

INJECTING KYBELLA® (deoxycholic acid) injection 10 mg/mL: DOSING & ADMINISTRATION

Injecting all submental fat in the approved Treatment Zone is imperative to treating
toward an optimal reduction of submental fullness.

Dosing standard
pdf-icon

The Established
Dosing Standard

  • A quick reminder of appropriate dosing for KYBELLA®
    1. Spacing Guide Reference for an easy way to translate grid dots to vials
Kybella Guide
pdf-icon

How-to Guide

  • Step-by-step instruction with visuals for administering KYBELLA®
    1. Identifying and marking the Treatment Zone
    2. Performing the injection
    3. And more!

ADDITIONAL HELPFUL RESOURCES

Advantage
Redirect icon

ALLERGAN ADVANTAGE

  • An online destination to access your favorite Allergan Aesthetics™ programs, product information, and so much more.
BrandBox
play-icon

BrandBox

  • Up-to-date tools and materials for your practice and patients

PLEASE CONTACT YOUR ALLERGAN AESTHETICS™ BUSINESS DEVELOPMENT MANAGER
IF YOU WOULD LIKE PRINTED TOOLS FOR YOUR PRACTICE!

Indication

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important safety information Contraindications

KYBELLA® is contraindicated in the presence of infection at the injection sites.

Warnings and Precautions Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

Injection Site Alopecia

Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

Adverse Reactions

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.